uniQure to Announce First Quarter 2025 Financial Results

Rhea-AI Summary

uniQure (NASDAQ: QURE) has announced it will report its first quarter 2025 financial results on Friday, May 9, 2025, before market open. The company will host its inaugural quarterly earnings conference call at 8:30 a.m. ET on the same day. This initiative to begin regular earnings calls comes as uniQure advances its pipeline and AMT-130 toward a BLA submission and potential commercialization, aiming to enhance engagement with the investment community.

The event will be accessible via webcast through uniQure's website, with a 90-day replay available afterward. Phone participants must pre-register through an online form to receive dial-in details and are advised to join 15 minutes before the start time.

News Market Reaction

-27.75%

1 alert

-27.75% News Effect

On the day this news was published, QURE declined 27.75%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

~ uniQure to host inaugural earnings call on Friday, May 9, 2025 at 8:30 a.m. ET ~

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 05, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report first quarter 2025 financial results before market open on Friday, May 9, 2025. Management will then host a conference call at 8:30 a.m. ET. As the Company advances its pipeline and AMT-130 toward a BLA submission and potential commercialization, uniQure is initiating quarterly earnings calls to provide regular updates on progress and to enhance engagement with the investment community.

The event will be webcast under the Events & Presentations section of uniQure’s website at https://www.uniqure.com/investors-media/events-presentations, and following the event a replay will be archived for 90 days. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone. If you are joining the conference call, please dial in 15 minutes before the start time.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe diseases. www.uniQure.com

uniQure Contacts:
FOR INVESTORS:	FOR MEDIA:
Chiara Russo	Tom Malone
Direct: 617-306-9137	Direct: 339-970-7558
Mobile: 617-306-9137	Mobile: 339-223-8541
c.russo@uniQure.com	t.malone@uniQure.com

FAQ

When will uniQure (QURE) report Q1 2025 earnings?

uniQure will report Q1 2025 earnings before market open on Friday, May 9, 2025.

What time is uniQure's Q1 2025 earnings call?

uniQure's Q1 2025 earnings call is scheduled for 8:30 a.m. ET on Friday, May 9, 2025.

Why is uniQure starting quarterly earnings calls in Q1 2025?

uniQure is initiating quarterly earnings calls as it advances its pipeline and AMT-130 toward BLA submission and potential commercialization, aiming to provide regular updates and enhance investor engagement.

How can investors access uniQure's Q1 2025 earnings call?

Investors can access the call via webcast on uniQure's website or by phone after registering through an online form to receive dial-in details.